MONOPROST

This brand name is authorized in Austria, Canada, Cyprus, Finland, France, Germany, Netherlands, Poland, Spain, Tunisia.

Active ingredients

The drug MONOPROST contains one active pharmaceutical ingredient (API):

1	Latanoprost UNII 6Z5B6HVF6O - LATANOPROST
	The active substance latanoprost, a prostaglandin F2α analogue, is a selective prostanoid FP receptor agonist which reduces the intraocular pressure (IOP) by increasing the outflow of aqueous humour. Reduction of the IOP in man starts about three to four hours after administration and maximum effect is reached after eight to twelve hours.
	Read more about Latanoprost

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01EE01	Latanoprost	S Sensory organs → S01 Ophthalmologicals → S01E Antiglaucoma preparations and miotics → S01EE Prostaglandin analogues
Discover more medicines within S01EE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02456230
DE	Bundesinstitut für Arzneimittel und Medizinprodukte	08880845, 09683495, 10981022, 11008045, 11051696, 11268071, 11368157, 11383754, 11886018, 12391371, 12393826, 12393832, 12470840, 13503168, 13600003, 13600026, 13706641, 14318651, 14318668, 14403233, 14852669, 14852675, 15266442, 16585327, 16585333
ES	Centro de información online de medicamentos de la AEMPS	3400926738266, 76616, BE428635
FI	Lääkealan turvallisuus- ja kehittämiskeskus	390531, 590147
FR	Base de données publique des médicaments	67303969
NL	Z-Index G-Standaard, PRK	103535
PL	Rejestru Produktów Leczniczych	100288877, 100378280
TN	Direction de la Pharmacie et du Médicament	8443131